The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review
Open accessAbstract
Background . Atherothrombotic disease, including coronary artery disease (CAD) and peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial infarction, stroke, limb ischemia, heart failure, and CV death. Aim . Evaluate the humanistic and economic burden of CAD and PAD and identify unmet needs through a comprehensive literature review. Methods . Relevant search terms were applied across online publication databases. Studies published between January 2010 and August 2017 meeting the inclusion/exclusion criteria were selected; guidelines were also included. Two rounds of screening were applied to select studies of relevance. Results . Worldwide data showed approximately 5–8% prevalence of CAD and 10–20% prevalence of PAD, dependent on the study design, average age, gender, and geographical location. Data from the REACH registry indicated that 18–35% of patients with CAD and 46–68% of patients with PAD had disease in one or more vascular beds. Use of medication to control modifiable CV risk factors was variable by country (lower in France than in Canada); statins and aspirin were the most widely used therapies in patients with chronic disease. Survival rates have improved with medical advancements, but there is an additional need to improve the humanistic burden of disease (i.e., associated disability and quality of life). The economic burden of atherothrombotic disease is high and expected to increase with increased survival and the aging population. Conclusion . CAD and PAD represent a substantial humanistic and economic burden worldwide, highlighting a need for new interventions to reduce the incidence of atherothrombotic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Baseline characteristics and medication use and clinical outcomes in patients with CAD and PAD from the REACH Registries of (a) Canada,a (b) France,b and (c) Germanyc [1, 2]. aPatients enrolled from January to October 2004; mean age 68.4 ± 9.9. bPercentage of patients experiencing at least one CV event (Figure (a): CAD n = 1356, PAD n = 146; Figure (b): CAD n = 2397, PAD n = 882; Figure (c): CAD n = 3328, PAD n = 1303). cPatients enrolled from December 2003 to June 2014; mean age 69.1–71.7 across risk groups. dPatients enrolled from December 2003 to June 2014; mean age 68.0–69.4 across risk groups. ACE, angiotensin-converting enzyme; ASA, acetylsalicylic acid; CAD, coronary artery disease; CV, cardiovascular; PAD, peripheral artery disease.](https://figures.cochat.ai/paper-figures/5e14fc8ebda846379e697620627d3268/burden-of-coronary-artery-disease-and-peripheral-artery-disease-a-literature-figure-1.jpg)
![Figure 2 The persistent risk of MACE (a) up to 3 years following an index MI (adapted from Blin et al., 2016) [3] and (b) up to 4.5 years following an index MI stratified by age (<72 years old versus ≥72 years old) and risk category (low versus higha) (adapted from Jernberg et al., 2015) [4]. aHigh-risk patients were predefined as those with ≥1 of the following risk factors prior to index; MI: diabetes mellitus, at least one MI prior to index MI event, CABG (proxy for multi-vessel CAD), PAD, stroke, heart failure, or diagnosis of chronic renal dysfunction. CABG, coronary artery bypass graft; CAD, coronary artery disease; CV, cardiovascular; HR, high risk; LR, low risk; MACE, major adverse cardiovascular events; MI, myocardial infarction; PAD, peripheral artery disease.](https://figures.cochat.ai/paper-figures/ef7f32f05aeb4415a5daae684132145b/burden-of-coronary-artery-disease-and-peripheral-artery-disease-a-literature-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mere presence of PAD significantly increases the risk of having atherosclerotic disease in other vascular beds.”
From Racial and Ethnic Disparities in Peripheral Artery Disease (2021) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Approximately, 46% to 68% of patients with PAD also had coronary artery disease (CAD) or cerebrovascular disease.[48][49][50]”
From Racial and Ethnic Disparities in Peripheral Artery Disease (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191 · cited 1×
“These conditions are characterized by progressive (CLI) or sudden onset (ALI) of pain at rest or nonhealing ischemic wounds or gangrene [27, 44, 45] and can ultimately lead to a loss of limbs [46].”
Background2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Kyu, H. H., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32335-3 · Cited by 4,081
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174526 · Cited by 3,708
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Hay, S. I., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32130-x · Cited by 2,083 · cited 1×
“of mortality and morbidity worldwide, atherothrombotic disease places a substantial medical and economic burden on society [7, 12].”
Background2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.007 · Cited by 1,941
Research works printed but not linked: 8
- 2017, Heart and Metabolism, 9
- 2015, La Revue Du Praticien, 65, 317
- 2016, Vascular Medicine (United Kingdom), 21, 331
- 2018, International Angiology, 37, 327
- 2016, JACC: Journal of the American College of Cardiology, 69, e71
- 2016, Circulation: Cardiovascular Quality and Outcomes, 9, 731
- 2013, Health and Quality of Life Outcomes, 11
- 2010, Circulation: Cardiovascular Quality and Outcomes, 3, 642
Cited by
Ralapanawa, U., & Sivakanesan, R. (2021) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.201217.001 · Cited by 669
“The risk of dying from CAD rises significantly with aging and systolic blood pressure is the most important modifiable risk factor explaining some additional CAD risks that come about with age [7,16,17].”
Zhou, Y., Zhou, H., Hua, L., Hou, C., Jia, Q., Chen, J., Zhang, S., Wang, Y., He, S., & Jia, E. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.009 · Cited by 249
Mitochondrial Structure and Function in Human Heart Failure
Hinton, A., Claypool, S. M., Neikirk, K., Senoo, N., Wanjalla, C. N., Kirabo, A., & Williams, C. R. (2024) · Circulation Research · doi:10.1161/circresaha.124.323800 · Cited by 220
Wadström, B. N., Wulff, A. B., Pedersen, K. M., Jensen, G. B., & Nordestgaard, B. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab705 · Cited by 234
Racial and Ethnic Disparities in Peripheral Artery Disease
Hackler, E. L., Hamburg, N. M., & White Solaru, K. T. (2021) · Circulation Research · doi:10.1161/circresaha.121.318243 · Cited by 141
Metadata
- Authors
- Bauersachs, R., Zeymer, U., Brière, J.-B., Marre, C., Bowrin, K., & Huelsebeck, M.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Klinikum Ludwigshafen (DE)
- Bayer (Germany) (DE)
- Creativ-Ceutical (France) (FR)
- Bayer (United Kingdom) (GB)
- Corresponding author
- Bauersachs, Rupert
- Venue
- Cardiovascular Therapeutics
- Publisher
- Wiley
- Published
- 2019-11-26
- Volume
- 2019
- Pages
- 1-9
- ISSN
- 1755-5914 (ISSN-L)
- 1755-5922
- PMC
- PMC7024142
- OpenAlex
- W2990657953
- Semantic Scholar
- 7306e92becdce616c64c569876ca723660f04cb3
- Cited by
- 449
- References
- 52
- Citations by year
- 2026: 39 · 2025: 80 · 2024: 118 · 2023: 102 · 2022: 64 · 2021: 38 · 2020: 8
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Therapeutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
- Funders
- Bayer AG
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Epidemiology › Healthcare Systems and Public Health
- Keywords
- coronary artery disease, peripheral arterial disease, atherothrombosis, disease burden, economic burden, humanistic burden, prevalence, quality of life, disability, statins, aspirin, cardiovascular risk management, survival rate, population aging, unmet needs
- MeSH terms
- Aged, Coronary Artery Disease, Female, Health Services Needs and Demand, Humans, Male, Prognosis, Risk Factors, Global Health, Incidence, Prevalence, Health Care Costs, Cost of Illness, Peripheral Arterial Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. https://app.cochat.ai/papers/10.1155/2019/8295054
- The paper
- Bauersachs, R., Zeymer, U., Brière, J.-B., Marre, C., Bowrin, K., & Huelsebeck, M. (2019). Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovascular Therapeutics. https://doi.org/10.1155/2019/8295054
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.